Brokerages Anticipate Foghorn Therapeutics Inc. (NASDAQ:FHTX) Will Post Quarterly Sales of $14.38 Million

Brokerages expect that Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) will report $14.38 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Foghorn Therapeutics’ earnings, with the highest sales estimate coming in at $18.75 million and the lowest estimate coming in at $10.00 million. Foghorn Therapeutics posted […]

Related Keywords

United States ,Canada ,Washington ,America , ,Morgan Stanley ,Life Insurance Co ,Zacks Investment Research ,Foghorn Therapeutics Inc ,America Corp ,Nasdaq ,Goldman Sachs Group ,Citigroup Inc ,Royal Bank ,Foghorn Therapeutics ,Get Rating ,Foghorn Therapeutic ,Investment Research ,Therapeutics Inc ,Gene Traffic Control ,Nasdaq Fhtx ,Fhtx ,Medical ,Ratings ,Consensus ,